AACCE Investments
ScreenerStocksIndicesPicksETFsBlogPricing

© 2026 ACCE Investments. All rights reserved.

ACCE Investments - Institutional-grade stock research for retail investors | BetaList
IndicesStocksETFsScreenerBlogGlossaryCompareMarket dataAdvisors
TermsPrivacyCookiesDisclaimerLegal noticeProfessional termsAboutContact
WEAV

Weave Communications Inc. Common Stock (WEAV) fair value

Healthcare · Health Information Services · NYSE · United States
$7.40+0.14%
Market cap $595MNext earnings 2026-10-29Updated Oct 18, 2026
Add earnings to calendarGoogle
Our verdict
Trades 77% above our fair value
Price
$7.40
Model fair valueConfidence: good
$4.18
Model range
$4.13 to $4.22
Fair value $4.18
Price $7.40
2 models fit Weave Communications Inc. Common Stock and they agree: 2 of 2 land within 15% of the average. The price is above every model.
Two or more of our models back this value.
Large premium(i)Silver63
Valued as a growth company: Discounted cash flow and P/E comparison.
ACCE opinionWeave Communications Inc. Common Stock (WEAV)
Fair value (2 models)
$4.18
ACCE price target
$7.05
Rating
Overvalued
Horizon
12 months
Fair value published on 18 Oct 2026, 15:06 CEST; previously $3.42 since 9 Oct 2026, 00:00 CEST.
ACCE price target published on 15 Oct 2026, 00:00 CEST.
Rating published on 18 Oct 2026, 15:06 CEST.
Price used: $7.40 at the close on 23 Oct 2026, 22:00 CEST.
Models: Discounted cash flow and P/E comparison.
Fair value: the average of the applicable valuation models (discounted cash flow, multiples, residual income, dividend discount, shareholder yield), each run on the latest financial statements and the market price shown. Opinion columns (fair value, target, rating) are shown apart from the data. Full methodology: acceinvestments.com/data/how-we-value-stocks
Full methodology
Conflicts of interest: The author holds no personal position in this security. General statement
Produced by ACCE Investments (acceinvestments.com)
Data
Price vs fair value
77.2% above
-43.6% to fair value
ACCE score
53
out of 100
Analysts
0% buy
4 covering
P/E
0.0x
forward 0.0x
1-year return
+8.0%
Dividend yield
0.00%

Weave Communications Inc. Common Stock in four questions

Plain answers, details below
Free accounts get 5 full stock pages a month, including the four answers.
OverviewAsk ACCEValuationQualityAnalystsSmart MoneyCompareNews and Record

Overview

ACCE thesis

Weave sells cloud software to healthcare providers, bundling patient communications such as texting, online scheduling, payments and electronic forms into one platform sold mostly to independent practices and specialty clinics. The structural appeal is the 72.4% gross margin, which says the software earns well on each dollar of revenue even though the company is still unprofitable at the operating line, with an operating margin of -6.2% and a return on equity of -25.1%. Revenue is growing 15.5%, so the question for a PM is whether operating leverage can close that gap as the sales base scales, which is the main thing to test on the next few quarterly reports. At a roughly $595M market cap with no index membership, the stock sits outside the bigger passive flows, which can mean less coverage and more price dislocation around earnings. The composite score of 51/100 reflects mixed fundamentals, so this is a name worth a deeper look only if the margin trajectory from here is the thesis you want to underwrite.

AI-assisted·How I use AIWritten Oct 18, 2026
⚠ Investor warnings · 2 flagsAI-assisted·How I use AI
  • high
    Unprofitable at operating level
    Operating margin is -6.2% and net margin -8.0%, with ROE at -25.1%. Earnings growth is 0.0% YoY, so the business is not yet converting its 72.4% gross margin into profit.
  • moderate
    Stock trades above model fair value
    The price of $7.40 sits 77.2% above the model fair value of $4.18, and 5.0% above the ACCE price target of $7.05. The valuation case rests on growth assumptions rather than current earnings.

AI research notes

AI-assisted·How I use AIWritten Oct 21, 2026 · figures from 2026-06-30 · prices to Oct 23, 2026
Why it could do well
  • Revenue grew 15.5% over the last year, and the company has averaged 24.5% growth per year over five years.
  • Free cash flow over the last twelve months was $15M, showing the business generates real cash despite reported losses.
  • The share price of $7.40 sits almost exactly on the analysts' mean price target of $7.40, a sign the market is not pricing in a big drop.
Why it could disappoint
  • The stock trades 77.2% above the model fair value of $4.18, and the consensus of both valuation models sits below the price.
  • Net margin of -8.0% and return on equity of -25.1% show the company is still losing money on the capital it uses.
  • Not one of the 4 analysts rates the stock Buy or Strong Buy, and the diluted share count rose 6.5% last fiscal year.
Each chip shows the exact figure and where it comes from. A claim without a source is not published.

Next results

Oct 29, 2026
We update the fair value about 2 days after the results, once the new figures are filed.Add to calendarGoogle

Walk me through this stock

Plain-English pros, cons, and what to watch. Pro feature.

PRO

Ask ACCE

Valuation

INVESTOR
Where WEAV's valuation models land
Price
$7.40
Model fair value
$4.18
Model range
$4.13 to $4.22
Fair value $4.18
Price $7.40
The price is above the whole model range.
Model
Fair value
Upside
Discounted cash flow
P/E comparison
Create a free account: 5 full stock pages a month, no card.

See what each model says, the assumptions behind it, the bad, normal and good cases, and why the fair value changed.

Quality

INVESTOR
Quality and conviction INVESTOR FEATURE

The full quality picture: a reason under every score, how the scores moved, and the conviction breakdown.

  • +A plain reason under every score
  • +Conviction breakdown and growth / value / quality / momentum scores
  • +Score history: how each score moved over time

Analysts

Wall Street consensus

Bearish0% buy · 4 covering analysts
● Strong buy 0● Buy 0● Hold 4● Sell 0● Strong sell 0
Analyst intelligence INVESTOR FEATURE

The full analyst picture: the price-target distribution against the current price, forward consensus estimates, and how ACCE's own models compare.

  • +Price-target low / average / high vs the current price, with implied upside
  • +Forward revenue and EPS consensus by fiscal year
  • +ACCE fair-value models lined up against the Street

Smart Money

PRO

In one line

Trades are only made public after a delay. We show the delay so you know how old the news is.

Company insiders
No trades filed
Last 90 days
Congress
No trades filed
Last 180 days
Average delay
No trades filed
From trade to public filing
Do politicians beat the market? Our backtest →
Smart money tracking PRO FEATURE

Follow the informed money: 13F position changes, insider and Congress trades, and 13D activist filings.

  • +Quarter-over-quarter institutional position changes
  • +Every insider and Congress trade, with how late it was disclosed
  • +Active 13D activist filings and top holders

Compare

Where it sits vs peers

News and Record

Press releases mentioning this company

Recent performance

1 week
+0.0%
1 month
+0.5%
3 months
+19.9%
6 months
+52.0%
YTD
-2.5%
1 year
+8.0%

SEC filings

Recommendation history, last 12 months

DateTypeNewPreviousPrice
18 Oct 2026, 15:06 CESTRatingOvervaluedfirst publication$7.40
18 Oct 2026, 15:06 CESTFair value$4.18$3.42$7.40
15 Oct 2026, 00:00 CESTACCE price target$7.05first publication$7.37
9 Oct 2026, 00:00 CESTFair value$3.42$3.35$7.37
29 Sept 2026, 00:00 CESTFair value$3.35$3.43$7.35
26 Sept 2026, 00:00 CESTFair value$3.43$3.47$7.34
15 Sept 2026, 00:00 CESTFair value$3.47$3.53$7.31
13 Sept 2026, 00:00 CESTFair value$3.53$3.58$7.31
30 Aug 2026, 00:00 CESTFair value$3.58$3.71$7.29
22 Aug 2026, 00:00 CESTFair value$3.71$3.67$7.31

This analysis is not personalised investment advice and does not take your situation, objectives or risk tolerance into account. ACCE Investments is not an authorised investment firm.

Investing in shares carries a risk of losing capital. The value of an investment can go down as well as up.

Valuation horizon: 12 months from the publication date.

Conflicts of interest. ACCE Investments is operated by Adrien Chantreuil, who may hold personal positions in the securities analysed. Positions are declared on each security. ACCE receives no payment from the companies analysed or from any intermediary for this analysis.

Get the full WEAV page, free

Every model, the scenarios, fair value history, AI notes and the four questions. 5 full stock pages every month on the free plan, no card.

Free accounts get 5 full stock pages a month, including the full page.

Snapshot

Growth52Value32Quality43Momentum83Total53
Valuation
Trailing P/E
0.0x
Forward P/E
0.0x
PEG
no data
P/B
6.40x
EV / Revenue
2.2x
Book value/sh
$1.06
Enterprise value
$562M
Profitability
ROE
-25.1%
FCF yield
2.55%
ROIC
-17.1%
Health and risk
Debt / equity
0.63
Dividend yield
0.00%
Beta
1.68

Price

+6.8% · 1Y

Ask anything about WEAV

Answered from Weave Communications Inc. Common Stock fundamentals + recent valuations. Every number shows its source and date.

This stock Peer Peer median weaker → stronger
P/Ebetter than 100% of peers
low 0.0x0.0xhigh 91.4x
ROEbetter than 33% of peers
low -101%-25%high 42%
Div yieldbetter than 50% of peers
low 0.0%0.0%high 4.8%

Peers

Prices Oct 23, 2026
CompanyPriceFair valuevs fair valueP/EROEQualityScore
WEAV Weave Communications Inc. Common Stock$7.40$477% above--25.1%4353
RAY-B.ST RaySearch Laboratories AB (publ)kr 191.90kr 16417% above30.9x26.0%8541
SOPH SOPHiA GENETICS SA Ordinary Shares$7.35----101.2%3850
EVH Evolent Health Inc Class A Common Stock$4.80----67.0%2148
EQS.PA Equasens Société anonyme€29.65€4128% below11.4x17.2%7557
NRC National Research Corporation Common Stock (Delaware)$21.93$10128% above91.4x42.0%5656
PHR Phreesia Inc. Common Stock$12.70$1619% below74.7x3.1%5567

Sector report card

Where WEAV ranks against its sector peers on each metric.

Computing percentiles…
  • Business Wire•Oct 12, 2026
    Weave and CareCredit Go Live with Integration That Places Patient Financing Inside the Front-Office Workflow
  • Business Wire•Sep 18, 2026
    Weave Ranks No. 1 in G2's Fall 2026 Patient Relationship Management Grid Report
  • Business Wire•Aug 20, 2026
    Weave's 2026 Pulse Survey Finds Healthcare Practices Are Ready for AI, but 60% Are Still Concerned About Data Privacy
10 more press releases · full archive on Investor+.INVESTOR
40 filings
October 2026
Oct 22
8-KCurrent reportPeriod 2026-10-22
View on SEC →
Oct 19
Form 4Insider transactionPeriod 2026-10-15
View on SEC →
Oct 13
8-KCurrent reportPeriod 2026-10-13
View on SEC →
37 more filings + AI summaries on Investor+.INVESTOR